Avenue Therapeutics, INC. (ATXI) SEC Filings — 2024
24 SEC filings for Avenue Therapeutics, INC. (ATXI) in 2024.
Filings
- Avenue Therapeutics Faces Nasdaq Delisting Warning — 8-K · Nov 29, 2024
- Fortress Biotech Amends Avenue Therapeutics Stake Filing — SC 13D/A · Nov 15, 2024
- Avenue Therapeutics, INC. SC 13G Filing — SC 13G · Nov 14, 2024
- Avenue Therapeutics Q3 2024: Minimal Financial Activity — 10-Q · Nov 14, 2024
- Avenue Therapeutics Appoints New CMO, CDO, and Directors — 8-K · Sep 27, 2024
- Avenue Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 9, 2024
- Avenue Therapeutics Appoints Dr. James N. Woody as CMO — 8-K · Jun 26, 2024
- Avenue Therapeutics Files 8-K Report — 8-K · May 23, 2024
- Avenue Therapeutics Files 8-K on Financials — 8-K · May 15, 2024
- Avenue Therapeutics Enters Material Definitive Agreement — 8-K · May 13, 2024
- Avenue Therapeutics, Inc. Announces Annual Meeting of Stockholders on June 24, 2024 — DEF 14A · May 6, 2024
- Avenue Therapeutics, INC. SC 13G/A Filing — SC 13G/A · May 2, 2024
- Avenue Therapeutics Files 8-K with Key Agreements and Equity Sales — 8-K · May 1, 2024
- Avenue Therapeutics Files 8-K: Security Holder Rights & Bylaws Modified — 8-K · Apr 26, 2024
- Fortress Biotech Amends Avenue Therapeutics Filing — SC 13D/A · Apr 17, 2024
- Avenue Therapeutics Faces Delisting Notice — 8-K · Mar 29, 2024
- Avenue Therapeutics Files 8-K on Financials — 8-K · Mar 18, 2024
- Avenue Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 18, 2024
- Avenue Therapeutics Closes $10M Public Offering — 8-K · Mar 15, 2024
- Avenue Therapeutics Files 8-K on Security Holder Vote — 8-K · Mar 8, 2024
- Avenue Therapeutics Amends Bylaws, Changes Fiscal Year — 8-K · Feb 23, 2024
- Avenue Therapeutics Files 8-K on Shareholder Vote Submission — 8-K · Jan 12, 2024
- Avenue Therapeutics Sells New Equity, Dilution Risk for ATXI Holders — 8-K · Jan 8, 2024
- Sabby Volatility Fund Discloses 661,056 Shares in Avenue Therapeutics — SC 13G/A · Jan 2, 2024